MannKind Co. (NASDAQ:MNKD) Shares Sold by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL decreased its holdings in MannKind Co. (NASDAQ:MNKD - Free Report) by 45.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 78,382 shares of the biopharmaceutical company's stock after selling 64,087 shares during the period. Tudor Investment Corp ET AL's holdings in MannKind were worth $504,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Vanguard Group Inc. lifted its position in MannKind by 2.7% during the fourth quarter. Vanguard Group Inc. now owns 16,058,557 shares of the biopharmaceutical company's stock valued at $103,257,000 after purchasing an additional 420,334 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of MannKind by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 6,374,274 shares of the biopharmaceutical company's stock worth $40,996,000 after acquiring an additional 35,346 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in MannKind by 275.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,887,609 shares of the biopharmaceutical company's stock valued at $31,427,000 after buying an additional 3,587,484 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in MannKind by 40.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,958,219 shares of the biopharmaceutical company's stock valued at $19,022,000 after buying an additional 855,261 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in MannKind by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,270,106 shares of the biopharmaceutical company's stock valued at $14,597,000 after buying an additional 45,277 shares during the last quarter. Hedge funds and other institutional investors own 49.55% of the company's stock.

MannKind Stock Up 5.5%

Shares of NASDAQ:MNKD traded up $0.25 during midday trading on Monday, reaching $4.81. The company's stock had a trading volume of 2,567,957 shares, compared to its average volume of 2,384,296. MannKind Co. has a 12-month low of $4.28 and a 12-month high of $7.63. The firm has a 50 day moving average of $4.89 and a 200-day moving average of $5.82. The firm has a market capitalization of $1.46 billion, a P/E ratio of 68.71 and a beta of 1.14.

MannKind (NASDAQ:MNKD - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.01. The business had revenue of $78.35 million for the quarter, compared to analysts' expectations of $75.86 million. MannKind had a net margin of 8.07% and a negative return on equity of 17.74%. The business's revenue for the quarter was up 18.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.05 EPS. On average, research analysts predict that MannKind Co. will post 0.1 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Wedbush reiterated an "outperform" rating and set a $11.00 price target on shares of MannKind in a report on Thursday, February 27th. StockNews.com raised shares of MannKind from a "hold" rating to a "buy" rating in a research report on Wednesday, March 19th. Finally, Mizuho assumed coverage on shares of MannKind in a research report on Thursday, April 10th. They set an "outperform" rating and a $12.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $10.00.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.